tradingkey.logo
tradingkey.logo
Buscar

Aclarion Inc

ACON
Añadir a la lista de seguimiento
3.160USD
-0.060-1.86%
Cierre 05/15, 16:00ETCotizaciones retrasadas 15 min
7.78MCap. mercado
PérdidaP/E TTM

Más Datos de Aclarion Inc Compañía

Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The Company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.

Información de Aclarion Inc

Símbolo de cotizaciónACON
Nombre de la empresaAclarion Inc
Fecha de salida a bolsaApr 22, 2022
Director ejecutivoNess (Brent)
Número de empleados6
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 22
Dirección8181 Arista Place
CiudadBROOMFIELD
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal80021
Teléfono18332752266
Sitio Webhttps://aclarion.com/
Símbolo de cotizaciónACON
Fecha de salida a bolsaApr 22, 2022
Director ejecutivoNess (Brent)

Ejecutivos de Aclarion Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Brent Ness
Mr. Brent Ness
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
6.30K
+99.79%
Dr. Scott Breidbart, M.D.
Dr. Scott Breidbart, M.D.
Independent Director
Independent Director
5.66K
--
Mr. Ryan Bond
Mr. Ryan Bond
Chief Strategy Officer
Chief Strategy Officer
1.00
--
Dr. Jeff Thramann, M.D.
Dr. Jeff Thramann, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. David Neal
Mr. David Neal
Director
Director
--
--
Mr. William Wesemann
Mr. William Wesemann
Lead Independent Director
Lead Independent Director
--
--
Ms. Amanda Williams
Ms. Amanda Williams
Independent Director
Independent Director
--
--
Mr. Steve Deitsch
Mr. Steve Deitsch
Independent Director
Independent Director
--
--
Mr. Gregory A. (Greg) Gould
Mr. Gregory A. (Greg) Gould
Chief Financial Officer
Chief Financial Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Brent Ness
Mr. Brent Ness
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
6.30K
+99.79%
Dr. Scott Breidbart, M.D.
Dr. Scott Breidbart, M.D.
Independent Director
Independent Director
5.66K
--
Mr. Ryan Bond
Mr. Ryan Bond
Chief Strategy Officer
Chief Strategy Officer
1.00
--
Dr. Jeff Thramann, M.D.
Dr. Jeff Thramann, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. David Neal
Mr. David Neal
Director
Director
--
--
Mr. William Wesemann
Mr. William Wesemann
Lead Independent Director
Lead Independent Director
--
--

Desglose de ingresos

La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.

Estadísticas de accionistas

Actualizado: jue., 14 de may
Actualizado: jue., 14 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
SEG Opportunity Fund LLC
9.91%
Geode Capital Management, L.L.C.
1.25%
UBS Financial Services, Inc.
0.39%
CAPTRUST Financial Advisors
0.35%
The Vanguard Group, Inc.
0.30%
Otro
87.80%
Accionistas
Accionistas
Proporción
SEG Opportunity Fund LLC
9.91%
Geode Capital Management, L.L.C.
1.25%
UBS Financial Services, Inc.
0.39%
CAPTRUST Financial Advisors
0.35%
The Vanguard Group, Inc.
0.30%
Otro
87.80%
Tipos de accionistas
Accionistas
Proporción
Corporation
9.91%
Investment Advisor
1.31%
Investment Advisor/Hedge Fund
1.25%
Individual Investor
0.07%
Hedge Fund
0.03%
Otro
87.43%

Participación institucional

Actualizado: mié., 1 de abr
Actualizado: mié., 1 de abr
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2026Q1
15
58.05K
2.32%
+16.68K
2025Q4
15
31.25K
1.59%
--
2025Q3
15
31.25K
0.88%
+26.14K
2025Q2
9
2.11K
0.08%
+1.65K
2025Q1
16
366.00
0.00%
+366.00
2024Q4
14
--
0.00%
--
2024Q3
14
--
0.00%
--
2024Q2
21
--
0.00%
--
2024Q1
22
--
0.00%
--
2023Q4
21
--
0.00%
--
Ver más

Actividad de los accionistas

Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
SEG Opportunity Fund LLC
244.04K
10.69%
+244.04K
--
Mar 25, 2026
Geode Capital Management, L.L.C.
2.06K
0.07%
--
--
Jan 31, 2026
UBS Financial Services, Inc.
1.05K
0.04%
+1.05K
--
Dec 31, 2025
CAPTRUST Financial Advisors
10.00K
0.35%
--
--
Dec 31, 2025
The Vanguard Group, Inc.
6.78K
0.24%
--
--
Feb 28, 2026
Ness (Brent)
13.00
0%
+10.00
+333.33%
Nov 26, 2025
Neal (David K)
2.00
0%
+2.00
--
May 09, 2025
Wesemann (William G)
1.00
0%
+1.00
--
May 09, 2025
Ver más

ETFs relacionados

Nombre
Proporción
Sin datos

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos

División de acciones

Fecha
Fecha ex-dividendo
Tipo
Relación
Mar 26, 2025
Merger
27→1
Mar 26, 2025
Merger
27→1
Mar 26, 2025
Merger
27→1
Mar 26, 2025
Merger
27→1
Jan 24, 2025
Merger
335→1
Jan 24, 2025
Merger
335→1
Fecha
Fecha ex-dividendo
Tipo
Relación
Mar 26, 2025
Merger
27→1
Mar 26, 2025
Merger
27→1
Mar 26, 2025
Merger
27→1
Mar 26, 2025
Merger
27→1
Jan 24, 2025
Merger
335→1
Jan 24, 2025
Merger
335→1
Jan 24, 2025
Merger
335→1
Jan 24, 2025
Merger
335→1
Jan 02, 2024
Merger
16→1
Jan 02, 2024
Merger
16→1
Ver más
KeyAI